可溶性CD105与子痫前期

Soluble Endoglin and Preeclampsia

可溶性CD105(sCD105)是一种存在于血液中分子质量为65ku的蛋白质,氨基酸序列对应于CD105蛋白氨基端的可溶性结构,可能是CD105经酶解脱落而成。子痫前期患者循环sCD105显著增高,而且sCD105增高发生在出现子痫前期临床症状前6～10周,其水平与子痫前期发病妊娠周及病情相关。在体外,sCD105可抑制转化生长因子β1(TGF-β1)诱导的人脐静脉内皮细胞的血管生成作用。注射载有sCD105基因的腺病毒可引起小鼠血管通透性增高,导致血管内皮细胞受损,并可使其血压增高,出现蛋白尿和其他类似子痫前期的病理变化。sCD105在子痫前期的变化及其在发病中的作用是子痫前期病因学与病理生理学研究的最新进展之一。

Soluble endoglin （sEng, sCD105 ）is a 65 ku serum protein and its aminoacid sequence corresponds to N-terminal soluble structure of full-length endoglin. It may be shed by membrane type matrix metalloprotease-1 （MT1-MMP）. The serum level of sEng was elevated in preeclamptic individuals and correlated with disease severity and gestational weeks. Besides, it was elevated 6-10 weeks before the onset of preeclampsia, sEng blocks transforming growth factor （TGF）-β1-mediated formation of human umbilical vein endothelial tubes in vitro and induces vascular permeability and hypertension in pregnant rats in vivo. The research of the effect of sEng in preeclampsia is one of the recent progresses in the pathogenesis of preeclampsia.